Assessing market opportunity for a new product launch
Our client required a quick and effective way of assessing the market opportunity of their recent product launch in order to maximise growth and uptake.
Our client required a quick and effective way of assessing the market opportunity of their recent product launch in order to maximise growth and uptake. However, as with most new products, the challenge was to set up useful metrics to track as a benchmark for growth against internal expectations and sales forecasts.
Lupus study reveals Benlysta favoured as future biologic of choice
With Benlysta’s approval and further drugs in the pipeline, the market for SLE is expected to grow substantially over the next 10 years, making this fast-changing disease area a key market to watch.
With Benlysta’s approval and further drugs in the pipeline, the market for SLE is expected to grow substantially over the next 10 years, making this fast-changing disease area a key market to watch. Wave one of Therapy Watch Lupus (SLE) provided us with a snapshot of the SLE market, identifying the current market trends which will most likely impact future brand strategy.
The study revealed that, despite its focus on SLE, Benlysta’s uptake has been more gradual than many predicted since its approval and it currently holds a similar proportion of the market as Rituximab/MabThera, which is prescribed off-label.
Leveraging the ASEAN market
If you can only research one ASEAN market, which one do you choose? Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to consider in deciding which markets to research.
Home to over half a billion people, the 10 nations that make up the ASEAN region constitute the eighth largest economy in the world. With pharmaceutical sales projected to exceed $20 billion in 2014, it’s an increasingly attractive and dynamic growth market for pharma manufacturers.
The Untapped Potential of ASEAN: The key growth factors
Published in eyeforpharma 26 June 2014 by Marc Yates
In this column, I continue to explore the opportunities for pharma in ASEAN, one of the world’s largest and fastest-growing economic territories.
Tracking significant changes in the US Rheumatoid Arthritis Market
The latest wave of Therapy Watch RA – US launched in June 2014 and is expected to reveal a very different rheumatoid arthritis (RA) market landscape, including the introduction of Pfizer’s small molecule, Xeljanz.
The study has been conducted amongst a panel 100 rheumatologists, submitting information on at least 700 RA patients.
In November 2012, the US Food and Drug Administration (FDA) approved Pfizer’s Xeljanz (tofacitinib) to treat adults with moderate to severe active RA who have had an inadequate response to, or who are intolerant of, methotrexate.